Modality
Radioligand
MOA
BCL-2i
Target
HER2
Pathway
Proteasome
PNHDLBCL
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
Apr 2018
→ May 2025
Phase 2Current
NCT07703792
920 pts·PNH
2018-04→2025-05·Completed
NCT06312113
2,155 pts·DLBCL
2022-05→TBD·Completed
3,075 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-1710mo agoPh3 Readout· PNH
2026-06-072mo awayBTD· PNH
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P2/3
Complet…
P2/3
Complet…
Catalysts
Ph3 Readout
2025-05-17 · 10mo ago
PNH
BTD
2026-06-07 · 2mo away
PNH
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07703792 | Phase 2/3 | PNH | Completed | 920 | CfB |
| NCT06312113 | Phase 2/3 | DLBCL | Completed | 2155 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 |